You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RLT

Showing 1 - 25 of 63
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))

Active, not recruiting
  • Prostate Cancer
  • +5 more
  • 131I-PSMA-1095 Radioligand Therapy (RLT)
  • Montreal, Quebec, Canada
    Stephan Probst
Oct 24, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Los Angeles, Houston (177Lu-PSMA-617)

Terminated
Has Results
  • Metastatic Castration Resistant Prostate Cancer
  • Los Angeles, California
  • +1 more
Mar 1, 2021

Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting
  • Prostate Cancer
  • Single-photon emission computed tomography
  • +2 more
  • Los Angeles, California
  • +2 more
Jun 22, 2022

Hemodialysis Complication Trial in Mus (Control, Experiment)

Completed
  • Hemodialysis Complication
  • Control
  • Experiment
  • Mus, Turkey
    Mus Alparlan University
May 20, 2022

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)

Recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • 225^Ac-PSMA-617
  • 68^Ga-PSMA-11
  • Darlinghurst, Australia
  • +1 more
Nov 23, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Image Guided Biopsy
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jun 17, 2022

Prostate Cancer Trial in Amsterdam, Groningen, Nijmegen (177Lu-PSMA-617)

Recruiting
  • Prostate Cancer
  • Amsterdam, Netherlands
  • +3 more
Oct 17, 2021

Cancer Trial in Meldola, Cesena ([177Lu]Lu-PSMA I&T)

Not yet recruiting
  • Cancer
  • [177Lu]Lu-PSMA I&T
  • Meldola, Forlì, Italy
  • +1 more
May 10, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Atlanta (procedure, radiation, other, drug)

Not yet recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Biospecimen Collection
  • +6 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 25, 2023

Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in Buffalo, New York, Cincinnati (SurVaxM for patients

Recruiting
  • Medulloblastoma
  • +7 more
  • SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
  • +2 more
  • Buffalo, New York
  • +2 more
Jul 8, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer Trial (Image Guided Biopsy)

Withdrawn
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Image Guided Biopsy
  • (no location specified)
Jul 22, 2020

Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Irvine, California
  • +2 more
Nov 27, 2023

Newly Diagnosed H3-mutated Glioma Trial in Germany (drug, biological, other)

Recruiting
  • Newly Diagnosed H3-mutated Glioma
  • Tecentriq 1200 MG in 20 ML Injection
  • +2 more
  • Mannheim, Baden-Wuerttemberg, Germany
  • +7 more
Jan 18, 2023

Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic Trial in San Francisco (GBM6-AD and poly-ICLC before and after

Active, not recruiting
  • Oligodendroglioma
  • +5 more
  • GBM6-AD and poly-ICLC before and after surgery
  • GBM6-AD and poly-ICLC after surgery only
  • San Francisco, California
    University of California
Sep 20, 2022

NSCLC, Progression of NSCLC, NSCLC Recurrent Trial in Saint Louis, Cincinnati (Docetaxel, Tergenpumatucel-L, Indoximod)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Apr 4, 2022

Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)

Recruiting
  • Ependymoma
  • +3 more
  • Augusta, Georgia
    Augusta University, Georgia Cancer Center
Dec 16, 2022

Prostatic Tumor Trial in Amsterdam, Utrecht (177Lu-PSMA-617, EBRT)

Recruiting
  • Prostatic Neoplasm
  • Amsterdam, Netherlands
  • +1 more
Dec 21, 2021

Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Stage IVB Prostate Cancer AJCC v8 Trial in San

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 20, 2023

Low Grade Glioma Trial in Pittsburgh (Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC)

Recruiting
  • Low Grade Glioma
  • Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
  • Pittsburgh, Pennsylvania
    Children's Hospital of Pittsburgh of UPMC
Aug 3, 2021

Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer, Advanced Prostate Carcinoma Trial in Homburg

Recruiting
  • Prostate Cancer Metastatic
  • +2 more
    • Homburg, Saarland, Germany
      Dept. of Nuclear Medicine, Saarland University
    Apr 4, 2021

    SWELE Program: An Unstructured Outdoor Play With

    Not yet recruiting
    • Specific Learning Disorder
    • +4 more
    • SWELE Programme
    • (no location specified)
    Oct 31, 2023

    Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

    Recruiting
    • Salivary Gland Cancer
    • +2 more
    • Nijmegen, Gelderland, Netherlands
      Radboudumc
    Oct 27, 2022

    Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Tumors Trial in United States (Olaparib, Tremelimumab)

    Active, not recruiting
    • Ovarian Cancer
    • +2 more
    • Tampa, Florida
    • +4 more
    Jan 12, 2021

    AML, Adult Trial in Italy (IDH mutation test performed at diagnosis or relapse until January 31st, 2019.)

    Completed
    • AML, Adult
    • IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
    • Alessandria, Italy
    • +23 more
    Dec 31, 2021